Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AG 337

Known as: AG-337, AG337 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Quinazolinesnolatrexednolatrexed dihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2003
Highly Cited
2003
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
BACKGROUND Some anticancer drugs inhibit thymidylate synthase (TS), a key enzyme for thymidine nucleotide biosynthesis. Cells can… Expand
Review
2000
Review
2000
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
Thymidylate synthase (TS) is an essential enzyme for the de novo synthesis of thymidylate and subsequently DNA synthesis. TS has… Expand
  • figure I
  • figure 2
  • figure 3
Highly Cited
2000
Highly Cited
2000
Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
Thymidylate synthase (TS) is an important target for cancer chemotherapy. However, several mechanisms of resistance to TS… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2000
Highly Cited
2000
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Gemcitabine (2'-2'-difluorodeoxycytidine; dFdC) is a deoxycytidine analogue which is effective against solid tumours, including… Expand
Highly Cited
2000
Highly Cited
2000
Clustering of Mutations in the First Transmembrane Domain of the Human Reduced Folate Carrier in GW1843U89-resistant Leukemia Cells with Impaired Antifolate Transport and Augmented Folate Uptake*
We have studied the molecular basis for the resistance of human CEM leukemia cells to GW1843, a thymidylate synthase inhibitor… Expand
  • figure 2
  • figure 1
  • table I
  • table II
  • figure 4
Highly Cited
1999
Highly Cited
1999
Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
Thymidylate synthase (TS), a critical enzyme in the de novo synthesis of thymidylate, is an important target for… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
1997
Highly Cited
1997
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
Oxaliplatin, classical [5-fluorouracil (5-FU)] and non-classical (AG337) thymidylate synthase inhibitors have shown promising… Expand
Highly Cited
1996
Highly Cited
1996
AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies
Abstract 3,4-Dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (AG337) is a water-soluble, lipophilic… Expand
  • figure 1
1996
1996
New Antifolates: Pharmacology and Clinical Applications.
  • Takimoto
  • The oncologist
  • 1996
    • Corpus ID: 11406217
Many new antifolate compounds with unique clinical properties are currently in clinical development. Some of these agents have… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Review
1995
Review
1995
Folate-based thymidylate synthase inhibitors as anticancer drugs.
The enzyme, thymidylate synthase (TS) is considered an important target for the development of new anticancer agents. Moreover… Expand
  • figure 1
  • figure 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE